Anais Roeser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anais Roeser has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Matthieu Mahévas
Service de Médecine Interne, Centre National de Référence des Cytopénies Auto‐Immunes de l'Adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP‐HP) Université Paris Est Créteil Créteil France
4 shared publications Marc Michel
Service de Médecine Interne, Centre de Référence des Cytopénies Auto‐immunes de l'adulte Centre Hospitalier Universitaire Henri‐Mondor, Assistance Publique‐Hôpitaux de Paris (AP‐HP), Université Paris‐Est Créteil (UPEC) Créteil France
3 shared publicationsAlexis Vandenberghe
Service de Médecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France; INSERM U955, Équipe 2, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil (UPEC), Créteil, France
2 shared publicationsAnnalisa Meola
Institut Pasteur, Université de Paris, Unité de Virologie Structurale, CNRS UMR 3569, Paris 75015, France
2 shared publicationsAurélien Sokal
Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMS 8253, Université de Paris, Paris, France; Service de Médecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France
2 shared publicationsBertrand Godeau
Service de Médecine Interne, Centre de Référence des Cytopénies Auto‐immunes de l'adulte Centre Hospitalier Universitaire Henri‐Mondor, Assistance Publique‐Hôpitaux de Paris (AP‐HP), Université Paris‐Est Créteil (UPEC) Créteil France
2 shared publications
Latest Publications
- 22 August 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (11) , 687-695
Évolution du choix de la médecine interne (et immunologie clinique) à l’issue des épreuves classantes nationales depuis 2010
- 22 August 2024
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 45 (11) , 687-695
Évolution du choix de la médecine interne (et immunologie clinique) à l’issue des épreuves classantes nationales depuis 2010
- Open Access
- 1 April 2023
- Published by Wiley in British Journal of Haematology
- Vol. 203 (1) , 43-53
B cells and antibodies in refractory immune thrombocytopenia
Summary: Immune thrombocytopenia (ITP) is an acquired bleeding disorder mediated by pathogenic autoantibodies secreted by plasma cells (PCs) in many patients. In refractory ITP patients, the persistence of splenic and bone marrow autoreactive long‐lived PCs (LLPCs) may explain primary failure of rituximab and splenectomy respectively. The reactivation of autoreactive memory B cells generating new autoreactive PCs contributes to relapses after initial response to rituximab. Emerging strategies targeting B cells and PCs aim to prevent the settlement of splenic LLPCs with the combination of anti‐BAFF and rituximab, to deplete autoreactive PCs with anti‐CD38 antibodies, and to induce deeper B‐cell depletion in tissues with novel anti‐CD20 monoclonal antibodies and anti‐CD19 therapies. Alternative strategies, focused on controlling autoantibody mediated effects, have also been developed, including SYK and BTK inhibitors, complement inhibitors, FcRn blockers and inhibitors of platelet desialylation.
- 1 April 2023
- Published by Wiley in British Journal of Haematology
- Vol. 203 (1) , 43-53
Open AccessB cells and antibodies in refractory immune thrombocytopenia
Summary: Immune thrombocytopenia (ITP) is an acquired bleeding disorder mediated by pathogenic autoantibodies secreted by plasma cells (PCs) in many patients. In refractory ITP patients, the persistence of splenic and bone marrow autoreactive long‐lived PCs (LLPCs) may explain primary failure of rituximab and splenectomy respectively. The reactivation of autoreactive memory B cells generating new autoreactive PCs contributes to relapses after initial response to rituximab. Emerging strategies targeting B cells and PCs aim to prevent the settlement of splenic LLPCs with the combination of anti‐BAFF and rituximab, to deplete autoreactive PCs with anti‐CD38 antibodies, and to induce deeper B‐cell depletion in tissues with novel anti‐CD20 monoclonal antibodies and anti‐CD19 therapies. Alternative strategies, focused on controlling autoantibody mediated effects, have also been developed, including SYK and BTK inhibitors, complement inhibitors, FcRn blockers and inhibitors of platelet desialylation.
- 13 January 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (8) , e246-e248
Successful outcome under multiple therapy in two cases of anti-MDA5 dermatomyositis with severe cardiomyopathy and interstitial lung disease
Anaïs Roeser, Jérôme Hadjadj, Lola Prat, Tali-Anne Szwebel, Yves Allenbach, Luc Mouthon, Marie-Pierre Revel, Benjamin Terrier; Successful outcome under multiple
- 13 January 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (8) , e246-e248
Successful outcome under multiple therapy in two cases of anti-MDA5 dermatomyositis with severe cardiomyopathy and interstitial lung disease
Anaïs Roeser, Jérôme Hadjadj, Lola Prat, Tali-Anne Szwebel, Yves Allenbach, Luc Mouthon, Marie-Pierre Revel, Benjamin Terrier; Successful outcome under multiple
- 10 May 2022
- Published by Wiley in British Journal of Haematology
- Vol. 198 (3) , 595-599
Characteristics, management and outcome of acquired amegakaryocytic thrombocytopenia
- 10 May 2022
- Published by Wiley in British Journal of Haematology
- Vol. 198 (3) , 595-599
Characteristics, management and outcome of acquired amegakaryocytic thrombocytopenia